How Surgical Robotics Can Make ‘Average Clinicians’ Better

Why does a promising MedTech acquisition on paper turn into 18 months of remediation and integration headaches?

• Not because the tech is bad.
• Not because the R&D team isn’t talented.
• But because the product wasn’t built with the acquirer in mind.

Remediation is the tax you pay for misalignment.

There’s a growing conversation around “Build-to-Buy” – not as a silver bullet, but as a way to reduce post-acquisition chaos and align development with strategic fit from the beginning.

At TTP, we work with clients at every stage of MedTech innovation – from end-to-end product development to new venture creation. Sometimes, a traditional outsourced R&D partnership is the right path. But when balance sheet treatment, speed and fit are key, Build-to-Buy offers another compelling route.

As Paul Galluzzo, head of our Surgical Intervention team, and Steve Bell, an independent Medtech startup advisor, discuss in this Crux of Medtech episode, Build-to-Buy can help de-risk product acquisition and sharpen focus from day one.